References (date) | Primary/ Secondary outcome measures (s) | Results |
---|---|---|
Castro Marrero et al. (2015) | NAD + /NADH CoQ10 ATP Citrate Synthase Lipoperoxides | NAD + /NADH: significantly higher (p < 0.001) CoQ10: significantly higher (p < 0.05) ATP: significantly higher (p < 0.05) Citrate Synthase: significantly higher (p < 0.05) Lipoperoxides: significantly lower (p < 0.05) |
Castro Marrero et al. (2016) | FIS-40 | Sleep: NS Pain: NS Fatigue: significantly lower (p = 0.03) |
Forsyth et al. (1999) | NA | NA |
Fukuda et al. (2016) | CES-D | NS. Increase in depressive symptom scores were dependent on increase in total plasma CoQ10 levels |
Kaiser et al. (2015) | NA | NA |
Menon et al. (2017) | Clinical Global Impression Scale (CGI) Patient Global Impression Measures (PGI) Insomnia Severity Index (ISI) | CGI: Significantly improved (p = 0.014) PGI: NS ISI: Significantly improved (p = 0.017) |
Montoya et al. (2018) | VAS for fatigue Concentration disturbance symptoms | VAS for fatigue: NS Concentration disturbance symptoms: NS |
Ostojic et al. (2016) | Muscular Creatine Levels Muscular Strength and Aerobic Power | Muscular creatine levels: Significantly higher (p < 0.01) Muscular Strength and Aerobic Power: (p < 0.05) |
Vermeulen et al. (2004) | Stroop attention concentration test McGill Pain Questionnaire | Stroop attention concentration test ALC: p < 0.001 PLC: p = 0.011 ALC + PLC: p = 0.004 McGill Pain Questionnaire ALC: NS PLC: p = NS ALC + PLC: NS |